News

Bausch & Lomb and Pfizer plan to collaborate on promoting both companies' prescription eye drugs in the US, aiming to significantly increase the support for the products, according to Reuters.

The five-year agreement involves Pfizer's glaucoma drug Xalatan and three B&L products: Alrex for conjunctivitis, Lotemax for inflammatory conditions and the combined anti-inflammatory and anti-infective medicine Zylet.

Financial terms between the companies were not released.

Providing exclusive eye care news, information and educational needs every week, including a FREE CET programme. Subscribe to Optician Print Edition.